SCHEMBL4692001

SCHEMBL4692001

O=C1CNCCN1Cc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ERCC1 P07992 1/20 0.45
ERCC4 Q92889 1/20 0.45
ALDH1A1 P00352 4/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SIGMAR1 Q99720 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
ADRB1 P08588 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
DRD3 P35462 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664775 0.92 SMN1; SMN2 (0.48) MEN1KMT2AERCC1ERCC4ALDH1A1
SCHEMBL14863940 0.85 HTR2C (0.43) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL2899901 0.85 ALDH1A1 (0.63) MEN1KMT2AALDH1A1POLBCYP2C9
SCHEMBL20129619 0.85 ALDH1A1 (0.42) MEN1KMT2AALDH1A1POLBL3MBTL1
SCHEMBL24648953 0.85 MGLL (0.43) MEN1KMT2AALDH1A1POLBL3MBTL1
SCHEMBL25271016 0.85 ALDH1A1 (0.42) ALDH1A1POLBL3MBTL1KDM4ECXCR4
SCHEMBL4786748 0.85 HTR2C (0.49) MEN1KMT2AERCC1ERCC4ALDH1A1
SCHEMBL92331 0.84 L3MBTL1 (0.56) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL23419850 0.84 SMN1; SMN2 (0.43) MEN1KMT2AALDH1A1POLBL3MBTL1
SCHEMBL4689238 0.84 SOS1 (0.46) ALDH1A1MAPTPOLBCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539714-B1 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-08-13 EP disclosed
EP-1539714-B1 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-08-13 EP disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
EP-1539714-A4 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2007-04-25 EP disclosed
US-20050288293-A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2005-12-29 US disclosed
EP-1539714-A2 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004047725-A2 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO. INC. (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288293-A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors TYMP, TOP1, REV1 MEN1 4574/4885KMT2A 2241/4885ERCC1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.